Publisher John Wiley and Sons Inc. has announced a partnership with The American Institute of Chemical Engineers (AIChE) and its Society for Biological Engineering (SBE), to launch a new quarterly, peer-reviewed, open access journal, Bioengineering & Translational Medicine. To be launched in 2016 as part of the Wiley Open Access portfolio, the new journal will be edited by Samir Mitragotri of the University of California, Santa Barbara.
Bioengineering & Translational Medicine will focus on ways chemical and biological engineering are driving innovations and solutions that impact clinical practice and commercial healthcare products. The journal will also highlight scientific and technical breakthroughs currently in the process of clinical and commercial translation.
Bioengineering & Translational Medicine welcomes manuscripts that provide new insights into translational hurdles, as well as examples of technologies that have demonstrated progress toward clinical or commercial translation. It invites contributions on topics including, but not limited to, drug delivery, drug discovery, tissue engineering, synthetic biology, gene therapy, computational modeling and bioinformatics, among others. The journal will include research reports, reviews, and rapid communications. Fully open access, Bioengineering & Translational Medicine research will be published under the CC-BY license.
Readership will include chemical engineers; biological engineers, biomolecular engineers, biomedical engineers and other engineers and scientists with interests in translational medicine, biotechnology, and biochemical and biomolecular engineering; and physicians and other healthcare researchers and professionals.
Brought to you by Scope e-Knowledge Center, a world-leading provider of abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
